Advertisement


Yasmin H. Karimi, MD, on Large B-Cell Lymphoma: Follow-up on Subcutaneous Epcoritamab Monotherapy

2024 ASCO Annual Meeting

Advertisement

Yasmin H. Karimi, MD, of the University of Michigan Comprehensive Cancer Center, discusses 2.5-year follow-up data on epcoritamab monotherapy for patients with relapsed or refractory large B-cell lymphoma. The subcutaneous regimen continues to demonstrate durable responses (Abstract 7039).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
EPCORE NHL-1 was a phase 2 trial evaluating Epcoritamab, a CD20, CD3-bispecific antibody in the treatment of relapsed refractory large cell lymphoma in the second line and beyond setting. In this poster, we presented longer term follow-up results, MRD results, as well as results from the optimization cohort. In the study, patients with relapsed refractory disease were enrolled and treated with Epcoritamab step-up dosing with full dose given on cycle 1, day 15. In the optimization cohort, the dosing schema remained the same. However, CRS prophylaxis was 15 milligrams, dexamethasone, and 500 milliliters of hydration. In the optimization cohort, hospitalization for CRS monitoring after full dose treatment was not required. 157 patients with large B-cell lymphoma were treated in the expansion cohort. The median age was 68 years, and patients had a median of three prior lines of treatment. This was a heavily pretreated patient population with 39% of patients having received a prior CAR-T and 83% refractory to the last line of treatment. The overall response rate in the study was 59% with 41% experiencing a complete response. A median follow-up time of 31 months. The median duration of CR has not yet been reached. An estimated 54% of complete responders remained in CR at 30 months. In patients in complete response, 80% of patients achieved MRD negativity at cycle 3 and 92% of patients experienced MRD negativity at any time point as assessed by clonoSEQ MRD. The most common treatment emergent adverse events were cytokine release syndrome, occurring at 51% of patients, fatigue, fever, neutropenia, diarrhea, nausea, anemia, and infections. There were 29% of patients that had a grade three or higher serious infection, and 10% discontinued therapy due to infection. As this trial was conducted during the COVID-19 pandemic and the omicron variant, there were 32 cases of COVID and nine deaths due to COVID. In the optimization cohort, the uniform use of dexamethasone and hydration, the incidents and severity of CRS occurred in about 37% of patients, and with the majority being low grade. Most CRS occurred after the first full dose of treatment and CRS events all resolved. Hospitalization was not mandatory and was at the discretion of the investigator. 60% of patients received outpatient therapy and only one patient required subsequent inpatient admission. After outpatient treatment, the remaining CRS events were managed without hospitalization. In summary, with over 2.5 years of follow-up of single agent Epcoritamab in relapse refractory large cell lymphoma, including high risk patient populations with prior CAR-T and primary refractory disease, the data continues to show ongoing durable responses in patients who achieve a CR and 62% of patients remain in CR at two years. In the optimization cohort data, in addition to another abstract printed in ash with outpatient Epcoritamab lends support to the safety of fully outpatient administration.

Related Videos

Leukemia
Lymphoma

Muhit Özcan, MD, on CLL/SLL: Report on a Still-Recruiting International Study of Nemtabrutinib, Venetoclax, and Rituximab

Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses the ongoing phase III BELLWAVE-010 study of nemtabrutinib plus venetoclax vs venetoclax plus rituximab in previously treated patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) (Abstract TPS7089).  

Breast Cancer

Eva M. Ciruelos, MD, PhD, on HER2-Positive and PAM50 Luminal Breast Cancer: Primary Results From the PATRICIA Trial

Eva M. Ciruelos, MD, PhD, of Spain’s Hospital 12 de Octubre and the Instituto de Investigación Sanitaria Hospital 12 de Octubre, discusses phase II data showing that the combination of palbociclib, trastuzumab, and endocrine therapy improved progression-free survival in patients with previously treated PAM50 luminal A or B, HER2-positive advanced breast cancer, as compared with treatment of physicians’ choice (Abstract 1008).

Pancreatic Cancer

Efrat Dotan, MD, on Pancreatic Cancer in Older Adults: Defining the Optimal Treatment Approach

Efrat Dotan, MD, of Fox Chase Cancer Center, discusses results from the phase II EA2186 trial, the first prospective study aiming to define the optimal treatment approach for vulnerable older adults with newly diagnosed metastatic pancreatic cancer (Abstract 4003).

Multiple Myeloma

Xavier P. Leleu, MD, PhD, on Multiple Myeloma: Update on Isatuximab, Lenalidomide, Dexamethasone, and Bortezomib

Xavier P. Leleu, MD, PhD, of France’s Université de Poitiers and Centre Hospitalier Universitaire de Poitiers, discusses phase III findings showing that isatuximab in combination with bortezomib, lenalidomide, and dexamethasone deepened responses and increased the rate of measurable residual disease negativity vs isatuximab with lenalidomide and dexamethasone in patients with newly diagnosed transplant-ineligible multiple myeloma (Abstract 7501).

Breast Cancer

Lisa A. Carey, MD, and Dejan Juric, MD, on Breast Cancer: Updates From the INAVO120 Trial

Lisa A. Carey, MD, of the University of North Carolina, Chapel Hill and UNC Lineberger Comprehensive Cancer Center, and Dejan Juric, MD, of the Massachusetts General Hospital Cancer Center, discuss phase III findings on first-line use of inavolisib or placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer who relapsed within 12 months of completing adjuvant endocrine therapy (Abstract 1003).

Advertisement

Advertisement




Advertisement